3-(3-nitrobenzyl)-7-hydroxy-4-methyl-6-chloro-2-oxo-2H-1-benzopyran | 393812-71-0

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 香豆素及其衍生物
• 英文名称: 3-(3-nitrobenzyl)-7-hydroxy-4-methyl-6-chloro-2-oxo-2H-1-benzopyran
• 英文别名: 6-chloro-7-hydroxy-4-methyl-3-(3-nitrobenzyl)-2H-chromen-2-one；6-chloro-7-hydroxy-4-methyl-3-[(3-nitrophenyl)methyl]chromen-2-one
• CAS: 393812-71-0
• 化学式: C₁₇H₁₂ClNO₅
• 分子量: 345.739
• InChiKey: HBXINJXKJHTYBP-UHFFFAOYSA-N

物化性质

• 沸点：
  574.6±50.0 °C(Predicted)
• 密度：
  1.480±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  24
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  92.4
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3-(3-nitrobenzyl)-7-hydroxy-4-methyl-6-chloro-2-oxo-2H-1-benzopyran 在 tin(II) chloride dihdyrate 、 sodium hydride 作用下， 以 乙酸乙酯 、 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 12.5h， 生成 dimethylcarbamic acid 3-(3-aminobenzyl)-6-chloro-4-methyl-2-oxo-2H-chromen-7-yl ester
  参考文献：
  名称：

  The sulfamide moiety affords higher inhibitory activity and oral bioavailability to a series of coumarin dual selective RAF/MEK inhibitors

  摘要：

  Introducing a sulfamide moiety to our coumarin derivatives afforded enhanced Raf/MEK inhibitory activity concomitantly with an acceptable PK profile. Novel sulfamide 17 showed potent HCT116 cell growth inhibition (IC50 = 8 nM) and good PK profile (bioavailability of 51% in mouse), resulting in high in vivo antitumor efficacy in the HCT116 xenograft (ED50 = 4.8 mg/kg). We confirmed the sulfamide moiety showed no negative impact on tests run on the compound to evaluate DMPK (PK profiles in three animal species, CYP inhibition and CYP induction) and the safety profile (hERG and AMES tests). Sulfamide 17 had favorable properties that warranted further preclinical assessment (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.10.001
• 作为产物：
  描述：

  4-氯间苯二酚 、 2-(3-nitrobenzyl)-3-oxo-butyric acid ethyl ester 在 硫酸 作用下， 以 水 为溶剂， 反应 12.0h， 以45%的产率得到3-(3-nitrobenzyl)-7-hydroxy-4-methyl-6-chloro-2-oxo-2H-1-benzopyran
  参考文献：
  名称：

  The sulfamide moiety affords higher inhibitory activity and oral bioavailability to a series of coumarin dual selective RAF/MEK inhibitors

  摘要：

  Introducing a sulfamide moiety to our coumarin derivatives afforded enhanced Raf/MEK inhibitory activity concomitantly with an acceptable PK profile. Novel sulfamide 17 showed potent HCT116 cell growth inhibition (IC50 = 8 nM) and good PK profile (bioavailability of 51% in mouse), resulting in high in vivo antitumor efficacy in the HCT116 xenograft (ED50 = 4.8 mg/kg). We confirmed the sulfamide moiety showed no negative impact on tests run on the compound to evaluate DMPK (PK profiles in three animal species, CYP inhibition and CYP induction) and the safety profile (hERG and AMES tests). Sulfamide 17 had favorable properties that warranted further preclinical assessment (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.10.001

文献信息

• ｐ27 단백질 유도제
  申请人：CHUGAI SEIYAKU KABUSHIKI KAISHA (Chugai Pharmaceutical Co., Ltd.) 추가이 세이야쿠 가부시키가이샤(520000045945)

  公开号：KR101511396B1

  公开（公告）日：2015-04-13

  본 발명은, 하기 일반식 (11) 로 나타내는 화합물 또는 그 약학상 허용할 수 있는 염을 유효 성분으로 하는 p27 단백질 유도제를 제공한다. [식 중, G1, G2, G3 및 G8은, 각각 독립적으로 -N= 등에서 선택되고, 고리 G6은 2 가의 아릴기 등에서 선택되고, A 는 아미노기 등에서 선택되고, G4 는 산소 원자 등에서 선택되고, G5 는 산소 원자 등에서 선택되고, G7 은 -CH2- 등에서 선택되고, R2 는 C1-6 알킬기 등에서 선택된다]

  本发明提供了一种以化合物或其药学上可接受的盐所表示的有效成分作为p27蛋白诱导剂的一般式(11)。[其中，G1、G2、G3和G8分别独立地选择自-N=等，环G6选择自2个芳基等，A选择自氨基等，G4选择自氧原子等，G5选择自氧原子等，G7选择自-CH2-等，R2选择自C1-6烷基等]
• Coumarin derivatives useful as tnf alpha inhibitors
  申请人：Cheng Fei Jie

  公开号：US20050014705A1

  公开（公告）日：2005-01-20

  Novel compounds composition capable of inhibiting TNFα and having antiimmunoinflammatory and autoimmune properties useful in a pharmaceutical composition, such as for a drug containing this as an active ingredient; and a therapeutic method with the use of these novel compounds.

  一种新型化合物组合，能够抑制TNFα，具有抗免疫炎症和自身免疫性质，在制药组合物中有用，例如作为含有此化合物作为活性成分的药物；以及使用这些新型化合物的治疗方法。
• Coumarin derivatives useful as TNFalpha inhibitors
  申请人：Cheng Fei Jie

  公开号：US20060020138A1

  公开（公告）日：2006-01-26

  Novel compounds composition capable of inhibiting TNFα and having anti immunoinflammatory and autoimmune properties useful in a pharmaceutical composition, such as for a drug containing this as an active ingredient; and a therapeutic method with the use of these novel compounds.

  一种能够抑制TNFα并具有抗免疫炎症和自身免疫特性的新型化合物组合，适用于制备药物组合物，例如含有该化合物作为活性成分的药物；以及使用这些新型化合物的治疗方法。
• COUMARIN DERIVATIVES USEFUL AS TNF ALPHA INHIBITORS
  申请人：Cheng Jie Fei

  公开号：US20100197917A1

  公开（公告）日：2010-08-05

  Novel compounds composition capable of inhibiting TNFα and having antiimmunionflammatory and autoimmune properties useful in a pharmaceutical composition, such as for a drug containing this as an active ingredient; and a therapeutic method with the use of these novel compounds.

  一种能够抑制TNFα并具有抗免疫炎症和自身免疫性质的新型化合物组合，可用于制备药物组合物，例如包含该化合物作为活性成分的药物；以及使用这些新型化合物的治疗方法。
• Novel Coumarin Derivative Having Antitumor Activity
  申请人：Iikura Hitoshi

  公开号：US20110092700A1

  公开（公告）日：2011-04-21

  The present invention provides a compound represented by general formula (1) below or a pharmaceutically acceptable salt thereof: wherein: X is selected from heteroaryl etc., Y 1 and Y 2 are selected from —N═ etc., Y 3 and Y 4 are selected from —CH═ etc., A is selected from sulfamide etc., R 1 is selected from hydrogen etc., and R 2 is selected from C 1-6 alkyl etc. The compound or salt has sufficiently high antitumor activity, and is useful in the treatment of cell proliferative disorders, particularly cancers. The present invention also provides a pharmaceutical composition containing the compound or salt as an active ingredient.

  本发明提供一种由下式（1）或其药学上可接受的盐所表示的化合物：其中，X选自杂环芳基等；Y1和Y2选自—N═等；Y3和Y4选自—CH═等；A选自磺酰胺等；R1选自氢等；R2选自C1-6烷基等。该化合物或盐具有足够高的抗肿瘤活性，并可用于治疗细胞增殖性疾病，特别是癌症。本发明还提供一种含有该化合物或盐作为活性成分的制药组合物。